Comparison 1. Probiotics plus conventional antifungal drugs versus conventional antifungal drugs.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical cure rate (short‐term)	5	695	Risk Ratio (M‐H, Fixed, 95% CI)	1.14 [1.05, 1.24]
2 Clinical cure rate (short‐term): sensitivity analysis	1	90	Risk Ratio (M‐H, Fixed, 95% CI)	1.41 [1.07, 1.84]
3 Clinical cure rate (short‐term): subgroup analysis	5	695	Risk Ratio (M‐H, Fixed, 95% CI)	1.14 [1.05, 1.24]
3.1 Intravaginal administration and single species of probiotics	4	605	Risk Ratio (M‐H, Fixed, 95% CI)	1.11 [1.02, 1.21]
3.2 Oral administration and multiple species of probiotics	1	90	Risk Ratio (M‐H, Fixed, 95% CI)	1.41 [1.07, 1.84]
4 Clinical cure rate (long‐term/1 month after treatment)	1	172	Risk Ratio (M‐H, Fixed, 95% CI)	1.07 [0.86, 1.33]
5 Clinical cure rate (long‐term/3 months after treatment)	1	172	Risk Ratio (M‐H, Fixed, 95% CI)	1.30 [1.00, 1.70]
6 Mycological cure rate (short‐term)	7	969	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [1.02, 1.10]
7 Mycological cure rate (short‐term): sensitivity analysis	1	90	Risk Ratio (M‐H, Fixed, 95% CI)	1.14 [0.97, 1.33]
8 Mycological cure rate (short‐term): subgroup analysis	7	969	Risk Ratio (M‐H, Fixed, 95% CI)	1.06 [1.02, 1.10]
8.1 Intravaginal administration and single species of probiotics	6	879	Risk Ratio (M‐H, Fixed, 95% CI)	1.05 [1.01, 1.10]
8.2 Oral administration and multiple species of probiotics	1	90	Risk Ratio (M‐H, Fixed, 95% CI)	1.14 [0.97, 1.33]
9 Mycological non‐cure (short‐term/Candida albicans versus non‐albicans)	1	90	Risk Ratio (M‐H, Fixed, 95% CI)	0.45 [0.16, 1.30]
9.1 Candida albicans	1	83	Risk Ratio (M‐H, Fixed, 95% CI)	0.49 [0.09, 2.52]
9.2 Non‐albicans	1	7	Risk Ratio (M‐H, Fixed, 95% CI)	0.42 [0.11, 1.53]
10 Mycological cure rate (long‐term/1 month after treatment)	3	627	Risk Ratio (M‐H, Random, 95% CI)	1.26 [0.93, 1.71]
10.1 Intravaginal administration of probiotics	2	588	Risk Ratio (M‐H, Random, 95% CI)	1.24 [0.83, 1.85]
10.2 oral administration of probiotics	1	39	Risk Ratio (M‐H, Random, 95% CI)	1.32 [0.99, 1.77]
11 Mycological cure rate (long‐term/1 month after treatment): sensitivity analysis	1	39	Risk Ratio (M‐H, Fixed, 95% CI)	1.32 [0.99, 1.77]
12 Mycological cure rate (long‐term/3 months after treatment)	1	172	Risk Ratio (M‐H, Fixed, 95% CI)	1.16 [1.00, 1.35]
13 Relapse rate	3	388	Risk Ratio (M‐H, Fixed, 95% CI)	0.34 [0.17, 0.68]
14 Rate of serious adverse events	2	440	Risk Ratio (M‐H, Fixed, 95% CI)	0.8 [0.22, 2.94]
15 Rate of non‐serious adverse events	7	906	Risk Ratio (M‐H, Fixed, 95% CI)	0.90 [0.48, 1.70]